Abstract
Glucagon-like peptide-1 (GLP-1) is a gut hormone that plays an important role in regulating glucose homeostasis by both its pancreatic and extrapancreatic activity. Defects of GLP-1 characterize type 2 diabetes as a primary or perhaps consequent phenomenon, resulting in inappropriately low insulin secretion after oral ingestion of nutrients. The discovery that cleavage by the ubiquitous enzyme dipeptidyl peptidase-IV (DPP-IV) is the primary route of GLP-1 metabolism formed the rationale behind the proposal to prevent degradation of endogenously released GLP-1 by DPP-IV inhibition as a novel approach to the management of type 2 diabetes. Enhanced insulin secretion as well as delayed gastric emptying, reduced glucagon secretion, and inhibited apoptosis of beta cells resulting from blockade of incretin degradation, have been proposed as the major actions of DPP-IV inhibitors as antidiabetic agents. Clinical studies to date indicate that DPP-IV inhibitors effectively ameliorate islet dysfunction and improve glucose control in patients with type 2 diabetes. They appear to have excellent therapeutic effectiveness as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. Their pharmacokinetic and pharmacodynamic profiles support once-daily dosing, with relatively few adverse effects.
Current Diabetes Reviews
Title: Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors
Volume: 5 Issue: 2
Author(s): Teresa Salvatore, Ornella Carbonara, Domenico Cozzolino, Roberto Torella and Ferdinando C. Sasso
Affiliation:
Abstract: Glucagon-like peptide-1 (GLP-1) is a gut hormone that plays an important role in regulating glucose homeostasis by both its pancreatic and extrapancreatic activity. Defects of GLP-1 characterize type 2 diabetes as a primary or perhaps consequent phenomenon, resulting in inappropriately low insulin secretion after oral ingestion of nutrients. The discovery that cleavage by the ubiquitous enzyme dipeptidyl peptidase-IV (DPP-IV) is the primary route of GLP-1 metabolism formed the rationale behind the proposal to prevent degradation of endogenously released GLP-1 by DPP-IV inhibition as a novel approach to the management of type 2 diabetes. Enhanced insulin secretion as well as delayed gastric emptying, reduced glucagon secretion, and inhibited apoptosis of beta cells resulting from blockade of incretin degradation, have been proposed as the major actions of DPP-IV inhibitors as antidiabetic agents. Clinical studies to date indicate that DPP-IV inhibitors effectively ameliorate islet dysfunction and improve glucose control in patients with type 2 diabetes. They appear to have excellent therapeutic effectiveness as monotherapy in patients inadequately controlled with diet and exercise and as add-on therapy in combination with metformin, thiazolidinediones, and insulin. Their pharmacokinetic and pharmacodynamic profiles support once-daily dosing, with relatively few adverse effects.
Export Options
About this article
Cite this article as:
Salvatore Teresa, Carbonara Ornella, Cozzolino Domenico, Torella Roberto and Sasso C. Ferdinando, Progress in the Oral Treatment of Type 2 Diabetes: Update on DPP-IV Inhibitors, Current Diabetes Reviews 2009; 5 (2) . https://dx.doi.org/10.2174/157339909788166819
DOI https://dx.doi.org/10.2174/157339909788166819 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Allergen-Specific Responses of CD19high and CD19low B Cells in Non-IgEMediated Food Allergy of Late Eczematous Reactions in Atopic Dermatitis: Presence of IL-17- and IL-32-Producing Regulatory B Cells (Br17 & Br32)
Inflammation & Allergy - Drug Targets (Discontinued) Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Genetic and Molecular Basis of QTL of Diabetes in Mouse: Genes and Polymorphisms
Current Genomics The Link Between CD6 and Autoimmunity: Genetic and Cellular Associations
Current Drug Targets Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Editorial (Thematic Issue: Molecular and Cellular Glyco-Science – Part I)
Current Protein & Peptide Science Role of Caspases in Activation-Induced Cell Death of Neuroglia
Current Enzyme Inhibition The Endocannabinoid System in Ageing: A New Target for Drug Development
Current Drug Targets 2 Receptor Specific Ligand Conjugated Nanocarriers: An Effective Strategy for Targeted Therapy of Tuberculosis
Current Drug Delivery Drug Delivery Systems for Imaging and Therapy of Parkinson's Disease
Current Neuropharmacology The Interaction Between Burn Injury and Vitamin D Metabolism and Consequences for the Patient
Current Clinical Pharmacology Novel Superactive Leptin Antagonists and their Potential Therapeutic Applications
Current Pharmaceutical Design Involvement of Membrane Channels in Autoimmune Disorders
Current Pharmaceutical Design Reviewing the Role of Resveratrol as a Natural Modulator of Microglial Activities
Current Pharmaceutical Design Galectins: Major Signaling Modulators Inside and Outside the Cell
Current Molecular Medicine Progress in Multiple Sclerosis Genetics
Current Genomics Neurotuberculosis: An Overview
Central Nervous System Agents in Medicinal Chemistry Targeting Toll-like Receptors in Autoimmunity
Current Drug Targets Regulation of Protective and Pathogenic Th17 Responses
Current Immunology Reviews (Discontinued) Targeting Microglial Polarization to Improve TBI Outcomes
CNS & Neurological Disorders - Drug Targets